Effect of Topical Epigallocatechin Gallate on Corneal Neovascularization in Rabbits

Abstract

Topical administration of EGCG effectively inhibits corneal neovascularization in rabbits. This inhibitory effect is probably related to the suppression of VEGF and COX-2 meditated angiogenesis.

Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

“…11,12 EGCG can inhibit angiogenesis by inhibiting the growth of endothelial cells and significantly reducing VEGF-induced corneal NV. 13 Green tea can also inhibit inflammation and angiogenesis. 14,15 Overall, EGCG could be a bifunctional antiangiogenic and anti-inflammatory agent for ocular NV treatment.…”

Inhibitory Effect of Topical Aflibercept on Corneal Neovascularization in Rabbits

“…Various agents have been suggested for the treatment of corneal NV, including steroids, 6 curcumin, 7 infliximab, 8 methotrexate, 9 suramin, 10 bevacizumab, 11-13 ranibizumab, 14 and epigallocatechin gallate. 15 Still, there has been no definitive treatment of choice in clinical practice.…”

Inhibition by Epigallocatechin Gallate of IL-1–Induced Urokinase-Type Plasminogen Activator Expression and Collagen Degradation by Corneal Fibroblasts

“…21,22 EGCG has thus been found to suppress tumor growth and angiogenesis by inhibiting MMP2 and -9 expression in tumor cells. 23,24 Topical administration of EGCG was also shown to inhibit corneal neovascularization in rabbits through suppression of the expression of VEGF and cyclooxygenase-2, 25 to attenuate inflammatory responses of the ocular surface in a mouse model of dry eye, 26 and to limit the development of corneal opacity caused by alkali-burn injury to the cornea in mice. 27 EGCG binds to uPA and interferes with its ability to recognize its substrates, thereby inhibiting its enzymatic activity.…”